Literature DB >> 10051646

Mutations in the organic cation/carnitine transporter OCTN2 in primary carnitine deficiency.

Y Wang1, J Ye, V Ganapathy, N Longo.   

Abstract

Primary carnitine deficiency is an autosomal recessive disorder of fatty acid oxidation caused by defective carnitine transport. This disease presents early in life with hypoketotic hypoglycemia or later in life with skeletal myopathy or cardiomyopathy. The gene for this condition maps to 5q31.2-32 and OCTN2, an organic cation/carnitine transporter, also maps to the same chromosomal region. Here we test the causative role of OCTN2 in primary carnitine deficiency by searching for mutations in this gene in affected patients. Fibroblasts from patients with primary carnitine deficiency lacked mediated carnitine transport. Transfection of patient's fibroblasts with the OCTN2 cDNA partially restored carnitine transport. Sequencing of the OCTN2 gene revealed different mutations in two unrelated patients. The first patient was homozygous (and both parents heterozygous) for a single base pair substitution converting the codon for Arg-282 to a STOP codon (R282X). The second patient was a compound heterozygote for a paternal 1-bp insertion producing a STOP codon (Y401X) and a maternal 1-bp deletion that produced a frameshift creating a subsequent STOP codon (458X). These mutations decreased the levels of mature OCTN2 mRNA and resulted in nonfunctional transporters, confirming that defects in the organic cation/carnitine transporter OCTN2 are responsible for primary carnitine deficiency.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10051646      PMCID: PMC26788          DOI: 10.1073/pnas.96.5.2356

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  18 in total

1.  Sudden neonatal death in carnitine transporter deficiency.

Authors:  P Rinaldo; C A Stanley; B Y Hsu; L A Sanchez; H J Stern
Journal:  J Pediatr       Date:  1997-08       Impact factor: 4.406

2.  Drug excretion mediated by a new prototype of polyspecific transporter.

Authors:  D Gründemann; V Gorboulev; S Gambaryan; M Veyhl; H Koepsell
Journal:  Nature       Date:  1994-12-08       Impact factor: 49.962

3.  Endocardial fibroelastosis and primary carnitine deficiency due to a defect in the plasma membrane carnitine transporter.

Authors:  M J Bennett; D E Hale; R J Pollitt; C A Stanley; S Variend
Journal:  Clin Cardiol       Date:  1996-03       Impact factor: 2.882

4.  Primary carnitine deficiency: heterozygote and intrafamilial phenotypic variation.

Authors:  B Garavaglia; G Uziel; F Dworzak; F Carrara; S DiDonato
Journal:  Neurology       Date:  1991-10       Impact factor: 9.910

Review 5.  Chronic cardiomyopathy and weakness or acute coma in children with a defect in carnitine uptake.

Authors:  C A Stanley; S DeLeeuw; P M Coates; C Vianey-Liaud; P Divry; J P Bonnefont; J M Saudubray; M Haymond; F K Trefz; G N Breningstall
Journal:  Ann Neurol       Date:  1991-11       Impact factor: 10.422

6.  Molecular and functional identification of sodium ion-dependent, high affinity human carnitine transporter OCTN2.

Authors:  I Tamai; R Ohashi; J Nezu; H Yabuuchi; A Oku; M Shimane; Y Sai; A Tsuji
Journal:  J Biol Chem       Date:  1998-08-07       Impact factor: 5.157

7.  cDNA sequence, transport function, and genomic organization of human OCTN2, a new member of the organic cation transporter family.

Authors:  X Wu; P D Prasad; F H Leibach; V Ganapathy
Journal:  Biochem Biophys Res Commun       Date:  1998-05-29       Impact factor: 3.575

Review 8.  Primary and secondary carnitine deficiency syndromes.

Authors:  R Pons; D C De Vivo
Journal:  J Child Neurol       Date:  1995-11       Impact factor: 1.987

9.  Activation of glucose transport by a natural mutation in the human insulin receptor.

Authors:  N Longo; S D Langley; L D Griffin; L J Elsas
Journal:  Proc Natl Acad Sci U S A       Date:  1993-01-01       Impact factor: 11.205

10.  Evidence for linkage of human primary systemic carnitine deficiency with D5S436: a novel gene locus on chromosome 5q.

Authors:  Y Shoji; A Koizumi; T Kayo; T Ohata; T Takahashi; K Harada; G Takada
Journal:  Am J Hum Genet       Date:  1998-07       Impact factor: 11.025

View more
  37 in total

Review 1.  Role of plasma membrane transporters in muscle metabolism.

Authors:  A Zorzano; C Fandos; M Palacín
Journal:  Biochem J       Date:  2000-08-01       Impact factor: 3.857

2.  Spontaneous development of intestinal and colonic atrophy and inflammation in the carnitine-deficient jvs (OCTN2(-/-)) mice.

Authors:  Prem S Shekhawat; Sonne R Srinivas; Dietrich Matern; Michael J Bennett; Richard Boriack; Varghese George; Hongyan Xu; Puttur D Prasad; Penny Roon; Vadivel Ganapathy
Journal:  Mol Genet Metab       Date:  2007-09-19       Impact factor: 4.797

Review 3.  Laboratory approach to mitochondrial diseases.

Authors:  D Parra; A González; C Mugueta; A Martínez; I Monreal
Journal:  J Physiol Biochem       Date:  2001-09       Impact factor: 4.158

Review 4.  Carnitine biosynthesis in mammals.

Authors:  Frédéric M Vaz; Ronald J A Wanders
Journal:  Biochem J       Date:  2002-02-01       Impact factor: 3.857

5.  Primary Carnitine (OCTN2) Deficiency Without Neonatal Carnitine Deficiency.

Authors:  L de Boer; L A J Kluijtmans; E Morava
Journal:  JIMD Rep       Date:  2012-12-29

6.  Identification of mutations and evaluation of cardiomyopathy in Turkish patients with primary carnitine deficiency.

Authors:  M Kilic; R K Ozgül; T Coşkun; D Yücel; M Karaca; H S Sivri; A Tokatli; M Sahin; T Karagöz; A Dursun
Journal:  JIMD Rep       Date:  2011-09-22

7.  Enzymes involved in L-carnitine biosynthesis are expressed by small intestinal enterocytes in mice: implications for gut health.

Authors:  Prem S Shekhawat; Srinivas Sonne; A Lee Carter; Dietrich Matern; Vadivel Ganapathy
Journal:  J Crohns Colitis       Date:  2012-09-21       Impact factor: 9.071

Review 8.  Carnitine and acylcarnitines: pharmacokinetic, pharmacological and clinical aspects.

Authors:  Stephanie E Reuter; Allan M Evans
Journal:  Clin Pharmacokinet       Date:  2012-09-01       Impact factor: 6.447

9.  SLC22A5/OCTN2 expression in breast cancer is induced by estrogen via a novel intronic estrogen-response element (ERE).

Authors:  Chunyu Wang; Ivan P Uray; Abhijit Mazumdar; Julie Ann Mayer; Powel H Brown
Journal:  Breast Cancer Res Treat       Date:  2012-01-03       Impact factor: 4.872

10.  Role of carnitine in disease.

Authors:  Judith L Flanagan; Peter A Simmons; Joseph Vehige; Mark Dp Willcox; Qian Garrett
Journal:  Nutr Metab (Lond)       Date:  2010-04-16       Impact factor: 4.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.